Transpapillary biliary stenting is a risk factor for pancreatic stones in patients with autoimmune pancreatitis

Background and study aim: Pancreatic stones occasionally develop in autoimmune pancreatitis (AIP), often worsen endocrine and exocrine functions, and occasionally cause pain attacks. However, the risks of pancreatic stones in AIP have been poorly studied. The aim of this study was to analyze the risk factors associated with pancreatic stone formation in cases of AIP.

Patients and methods: In total, 50 patients with AIP (39 males, 11 females; mean age 64.0 years), followed up for at least a year, were analyzed for their demographic and clinical findings and pancreatic stone occurrence.

Results: In total, 50 patients were followed up for an average of 59.7 (12 – 120) months, with steroid treatment in 44 patients (88 %); pancreatic stones occurred in 14 (28 %) patients after the diagnosis of AIP and endoscopic treatment was needed in one patient with pain attack. The pancreatic stones appeared only in patients with long follow-up period (P < 0.001, 83.9 months vs. 49.6 months), biliary stenting (odds ratio [OR]: 8.40, P = 0.010), relapse (OR: 6.20, P = 0.023), jaundice (OR: 5.40, P = 0.019), and swelling of the duodenal major papilla (OR: 4.67, P = 0.040). Biliary stenting was placed for an average of 9.9 months in 27 patients. Multivariate analysis revealed a significant association only with biliary stenting (P = 0.011). The stones appeared relatively earlier in patients with stones in the main pancreatic duct or Santorini duct (22.1 months) than in patients where pancreatic stones developed elsewhere (53.4 months) (P = 0.018).

Conclusions: The risk of pancreatic stone development should be taken into account when a biliary stent is placed in patients with AIP.

• References

• 1 Okazaki K, Yanagawa M, Mitsuyama T et al. Recent advances in the concept and pathogenesis of IgG4-related disease in the hepato-bilio-pancreatic system. Gut Liver 2014; 8: 462-470
• 2 Shimosegawa T, Chari ST, Frulloni L et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas 2011; 40: 352-358
• 3 Kamisawa T, Chari ST, Lerch MM et al. Recent advances in autoimmune pancreatitis: type 1 and type 2. Gut 2013; 62: 1373-1380
• 4 Notohara K, Burgart LJ, Yadav D et al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am J Surg Pathol 2003; 27: 1119-1127
• 5 Matsubayashi H, Uesaka K, Kanemoto H et al. Reduction of splenic volume by steroid therapy in cases with autoimmune pancreatitis. J Gastroenterol 2013; 48: 942-950
• 6 Matsubayashi H, Iwai T, Matsui T et al. Pancreatic cystic lesions with atypical steroid response should be carefully managed in cases of autoimmune pancreatitis. J Gastroenterol Hepatol 2016; 31: 270-276
• 7 Kamisawa T, Shimosegawa T, Okazaki K et al. Standard steroid treatment for autoimmune pancreatitis. Gut 2009; 58: 1504-1507
• 8 Matsubayashi H, Yoneyama M, Nanri K et al. Determination of steroid response by abdominal ultrasound in cases with autoimmune pancreatitis. Dig Liver Dis 2013; 45: 1034-1040
• 9 Nishimori I, Tamakoshi A, Kawa S et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas 2006; 32: 244-248
• 10 Hirano K, Isogawa A, Tada M et al. Long-term prognosis of autoimmune pancreatitis in terms of glucose tolerance. Pancreas 2012; 41: 691-695
• 11 Hirano K, Tada M, Isayama H et al. High alcohol consumption increases the risk of pancreatic stone formation and pancreatic atrophy in autoimmune pancreatitis. Pancreas 2013; 42: 502-505
• 12 Ito T, Kawabe K, Arita Y et al. Evaluation of pancreatic endocrine and exocrine function in patients with autoimmune pancreatitis. Pancreas 2007; 34: 254-259
• 13 Frulloni L, Scattolini C, Katsotourchi AM et al. Exocrine and endocrine pancreatic function in 21 patients suffering from autoimmune pancreatitis before and after steroid treatment. Pancreatology 2010; 10: 129-133
• 14 Maruyama M, Watanabe T, Kanai K et al. Extracorporeal shock wave lithotripsy treatment of pancreatic stones complicated with advanced stage autoimmune pancreatitis. BMC Gastroenterol 2015; 15: 28
• 15 Maruyama M, Arakura N, Ozaki Y et al. Risk factors for pancreatic stone formation in autoimmune pancreatitis over a long-term course. J Gastroenterol 2012; 47: 553-560
• 16 Takayama M, Hamano H, Ochi Y et al. Recurrent attacks of autoimmune pancreatitis result in pancreatic stone formation. Am J Gastroenterol 2004; 99: 932-937
• 17 Imai K, Matsubayashi H, Fukutomi A et al. Endoscopic ultrasonography-guided fine needle aspiration biopsy using 22-gauge needle in diagnosis of autoimmune pancreatitis. Dig Liver Dis 2011; 43: 869-874
• 18 Matsubayashi H, Fukutomi A, Kanemoto H et al. Risk of pancreatitis after endoscopic retrograde cholangiopancreatography and endoscopic biliary drainage. HPB 2009; 11: 222-228
• 19 Kubota K, Iida H, Fujisawa T et al. Clinical significance of swollen duodenal papilla in autoimmune pancreatitis. Pancreas 2007; 35: e51-60
• 20 Hart PA, Kamisawa T, Brugge WR et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62: 1771-1776
• 21 Sawai H, Matsubayashi H, Tanaka M et al. A case of autoimmune pancreatitis with metachronous appearance of idiopathic thrombocytopenic purpura. Clin J Gastroenterol 2010; 3: 243-247
• 22 Matsubayashi H, Kimura H, Tobisu K et al. Autoimmune pancreatitis accompanied with recurrence of bladder cancer: difficulty in diagnosis and management of systemic lesions in a case with autoimmune pancreatitis. J Pancreas 2012; 13: 446-450
• 23 Ito T, Otsuki M, Itoi T et al. Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan. J Gastroenterol 2007; 42: 291-297
• 24 Nagai H, Ohtsubo K. Pancreatic lithiasis in the aged. Its clinicopathology and pathogenesis. Gastroenterology 1984; 86: 331-338
• 25 Lankisch PG, Otto J, Erkelenz I et al. Pancreatic calcifications: no indicator of severe exocrine pancreatic insufficiency. Gastroenterology 1986; 90: 617-621
• 26 Cavallini G, Talamini G, Vaona B et al. Effect of alcohol and smoking on pancreatic lithogenesis in the course of chronic pancreatitis. Pancreas 1994; 9: 42-46
• 27 Vonlaufen A, Wilson JS, Apte MV. Molecular mechanisms of pancreatitis: current opinion. J Gastroenterol Hepatol 2008; 23: 1339-1348
• 28 Ko SB, Mizuno N, Yatabe Y et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology 2010; 138: 1988-1996
• 29 Shimizu K. Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis. J Gastroenterol 2008; 43: 823-832
• 30 Witt H, Apte MV, Keim V et al. Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy. Gastroenterology 2007; 132: 1557-1573
• 31 Costamagna G, Tringali A, Shah SK et al. Long-term follow-up of patients after endoscopic sphincterotomy for choledocholithiasis, and risk factors for recurrence. Endoscopy 2002; 34: 273-279
• 32 Doi S, Yasuda I, Mukai T et al. Comparison of long-term outcomes after endoscopic sphincterotomy versus endoscopic papillary balloon dilation: a propensity score-based cohort analysis. J Gastroenterol 2013; 48: 1090-1096